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Bladder  cancer  has  been  associated  with  chronic  arsenic  exposure.  Monomethylarsonous
acid  [MMA(III)]  is a metabolite  of  inorganic  arsenic  and  has  been  shown  to transform  an
immortalized  urothelial  cell  line  (UROtsa)  at concentrations  20-fold  less  than  arsenite.
MMA(III)  was used  as a  model  arsenical  to  examine  the  mechanisms  of arsenical-induced
transformation  of  urothelium.  A  previous  microarray  analysis  revealed  only  minor  changes
in gene  expression  at 1  and  2 months  of chronic  exposure  to MMA(III),  contrasting  with
substantial  changes  observed  at 3 months  of exposure.  To address  the  lack  of  information
between  2 and  3  months  of exposure  (the  critical  period  of transformation),  the  expression
of  select  pathway  marker  genes  was  measured  by  PCR array  analysis  on  a  weekly  basis.  Cell
proliferation rate,  anchorage-independent  growth,  and  tumorigenicity  in SCID  mice  were
also assessed  to determine  the  early,  persistent  phenotypic  changes  and  their  association
with  the  changes  in  expression  of  these  selected  marker  genes.  A  very  similar  pattern  of
alterations  in these  genes  was  observed  when  compared  to the  microarray  results,  and
suggested that  early  perturbations  in  cell  signaling  cascades,  immunological  pathways,
cytokine  expression,  and  MAPK  pathway  are particularly  important  in  driving  malignant
transformation.  These  results  showed  a  strong  association  between  the  acquired  pheno-
typic changes  that  occurred  as  early  as  1–2  months  of  chronic  MMA(III)  exposure,  and  the
observed  gene  expression  pattern  that is  indicative  of  the  earliest  stages  in  carcinogenesis.
©  2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe CC  B
. IntroductionArsenic is a ubiquitous environmental metalloid.
hronic exposure to low concentrations of inorganic
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arsenic increases risks for the development of skin, lung,
and  bladder cancers [1,2]. The exact biological events by
which  inorganic arsenic causes cancer have not been fully
elucidated. However, oxidative stress, increased cell pro-
liferation, inhibited DNA repair, genotoxicity, and altered
cellular signals have all been suggested as critical events in
arsenic-induced carcinogenesis [3–5].
Most human exposure to arsenic is via ingestion of
inorganic arsenate [As(V)] and arsenite [As(III)]. Biotrans-
formation of these inorganic arsenic species in humans
is is an open access article under the CC BY-NC-ND license
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produces methylated metabolites, that are found in
the  urine of arsenic-exposed individuals. As the urine
accumulates in the bladder, the bladder urothelium
is clearly exposed to the inorganic arsenic species as
well  as the methylated metabolites [6–8]. Additionally,
in vitro studies of urothelial cells (UROtsa) demon-
strated that these cells accumulated a greater amount
of  arsenic species when compared to human primary
hepatocytes [9].
Both  the trivalent arsenic metabolites, monomethy-
larsonous acid [MMA(III)] and dimethylarsinous acid
[DMA(III)], have been shown to be more cytotoxic than
both  the methylated pentavalent forms and inorganic
arsenic [10–12]. In particular, MMA(III) has been shown
to  be a potent generator of reactive oxygen species
(ROS), and appears to be more clastogenic than inorganic
arsenic [13–15]. Cytotoxicity assays of inorganic arsenic
and  MMA(III) have been performed in UROtsa, where
MMA(III) had a 20-fold more toxic response than As(III),
supporting earlier work that methylated trivalent arsenic
species were highly toxic to immortalized rat (MYP3) and
human  (1T1) urothelial cells [16,17]. The IC50 value for
MMA(III) was determined to be 5 M in UROtsa cells, with
no  signiﬁcant effects observed on cell morphology and
mitochondrial activity during 24 h of exposure [16]. Thus
0.05  M (50 nM)  has been used in this current study and
several others [18–21] as a non-cytotoxic concentration for
long-term  exposure studies.
Inorganic  arsenic and its methylated metabolites have
been  shown to modify the expression of genes, and cause
distinct proﬁles of cellular responses in urothelial cells
and  keratinocytes [22–25]. MMA(III) appeared to exhibit
a  greater carcinogenic potential, more pro-inﬂammatory
signals, and altered expression of growth factors in human
keratinocytes compared to inorganic arsenic exposure.
Likewise, fundamental similarities and differences were
found  between As(III)-, MMA(III)-, and DMA(III)-induced
transcriptional perturbations in urothelial cells (SV-HUC-
1),  and that some of these changes were attributed to
epigenetic alterations [24]. Even with these bodies of work,
the  understanding of the relationship between chronic
MMA(III) exposure and the development of bladder cancer
is  still limited.
UROtsa cells chronically exposed to 50 nM MMA(III)
for a period of 3 months underwent phenotypic changes
consistent with malignant transformation, i.e., increased
rate of proliferation, anchorage-independent growth, and
formation  of tumors in immuno-compromised mice [21].
These  acquired phenotypic changes were sustained even
after  withdrawal of MMA(III). Additionally, chronic expo-
sure  to MMA(III) had substantially impacted the global
expression of genes at 3 months of exposure with roughly
8.4%  of genes signiﬁcantly changed from 30,000 genes
assessed [26]. Surprisingly, signiﬁcantly altered genes in
the  ﬁrst and second months of exposure amounted to
less  than 1% of the total genes assessed. The transition
from a normal to a malignant phenotype occurred between
the  second and third months of exposure. The early
changes described by the gene array analysis implicated the
involvement of perturbed immune and inﬂammatory path-
ways  and related signaling. Similar observations of alteredports 1 (2014) 421–434
pro-inﬂammatory genes have been observed previously
using the same model [18,19].
Since the gene array study in UROtsa cells was only
performed at monthly intervals, resolving the window of
transformation between 2 and 3 months of exposure into
shorter  intervals should deﬁne the speciﬁc changes that
induce  malignant transformation with chronic MMA(III)
exposure. Therefore, the goal of the present study was
to  dissect the gene expression changes at weekly inter-
vals  in UROtsa cells chronically exposed to a non-cytotoxic
concentration of MMA(III) between 2 and 4 months of
exposure to resolve the changes contributing to malig-
nant transformation. The study used a customized PCR
array  to proﬁle the expression of selected genes asso-
ciated with several important pathways, i.e., apoptosis,
immune/inﬂammatory response, and proliferation as wells
as  correlate the phenotypic changes that occur within
that timeframe. Concomitantly, cell growth kinetics,
anchorage-independent growth, and tumorigenicity in
SCID  mice were also assessed to determine the earliest and
persistent  phenotypic changes and their association with
the  changes in expression of selected genes.
2. Materials and methods
2.1.  Reagents
Dulbecco’s modiﬁed Eagle medium (DMEM), fetal
bovine serum (FBS), antibiotic–antimycotic solution (con-
taining  penicillin, streptomycin, and amphotericin B),
and  0.25% trypsin–ethylenediaminetetraacetic acid (EDTA)
were  acquired from Gibco Invitrogen/Molecular Probes
Corporation (Carlsbad, CA). Diiodomethylarsine [MMA(III)
iodide, CH3AsI2] was  prepared by the Synthetic Chemistry
Facility Core (Southwest Environmental Health Sciences
Center, Tucson, AZ) using the technique of Millar et al.
[27].  Dissolution of diiodomethylarsine in water yields
monomethylarsonous acid [MMA(III)] and the concentra-
tion of MMA(III) was veriﬁed using high performance liquid
chromatography-inductively coupled mass spectrometry
(HPLC ICP-MS) in the analytical core of our NIEHS Super-
fund  Research Program. MMA(III) solutions in distilled,
de-ionized water were stable for approximately 4 months
at  4 ◦C with no degradation observed when monitored
using HPLC ICP-MS [28].
2.2.  Preparation of MMA(III) dosing solution
Preparation of dosing solution and procedures were
derived from Bredfeldt et al. [16]. Pure MMA(III) was stored
in  ampules at 4 ◦C. Fresh stock solutions of 25 mM MMA(III)
were made and diluted to a ﬁnal concentration of 5 M
prior  to dosing (1:100 dilution) to obtain a ﬁnal concentra-
tion of 50 nM MMA(III) in the culture media. The level of
MMA(III) used in this study (50 nM)  represents a relevant
physiological concentration as this speciﬁc metabolite has
been  detected in the urine of humans with MMA(III) levels
at  or near 50 nM when exposed to environmentally rele-
vant  concentrations of inorganic arsenic in their drinking
water [29,30]. All dosing solutions were sterile ﬁltered with
a  0.2 M Acrodisc (Sigma–Aldrich) and stored in sealed,
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terile tubes at 4 ◦C that were opened only for dosing in a
terile  cell culture hood.
.3.  Cell culture
UROtsa cells [31] were a generous gift from Drs. Don-
ld  and Maryann Sens (University of North Dakota, ND).
ell  culture conditions were derived from those previ-
usly described by Rossi et al. [32] and Bredfeldt et al.
33].  UROtsa cells (beginning at passage 26) were cultured
n  a growth media of DMEM containing 5% (v/v) FBS and
%  (v/v) antibiotic–antimycotic. Cultured cells were incu-
ated  at 37 ◦C and 5% CO2. Conﬂuent cells were removed
rom plates with trypsin–EDTA (0.25%) and subcultured at
 ratio of 1:3. All cell lines used in this study tested negative
or  the presence of mycoplasma contamination. Arsenical-
reated cultures of UROtsa were continuously grown in
edia  supplemented with 50 nM MMA(III) and refreshed
very 2 days.
.4. Control cell lines
The  control cell lines consisted of untreated passage-
atched UROtsa cells and a treated positive control cell line
erived  from [21]. Treated positive control cell line began
ith  malignant URO-MSC36 and exposed for an additional
onth to 50 nM MMA(III).
.5. Quantitative reverse transcription PCR
Total RNA was isolated from all cells using the RNeasy
ini Kit (Qiagen, Valencia, CA), and DNase digestion per-
ormed  with DNase I Set (Qiagen). RNA quantiﬁcation was
erformed on NanoDrop 2000 Spectrophotmeter (Thermo
cientiﬁc). Gene expression was measured using quantita-
ive  real-time reverse transcription (QRT)-PCR on a custom
T2 ProﬁlerTM 96-well PCR Array (Qiagen) according to
anufacturer’s protocols. The selected panel of genes
sed in this study is shown in Table 1A. Brieﬂy, total
NA from controls and treated UROta cells was  reverse
ranscribed to complementary DNA (cDNA) using the RT2
irst Strand Kit (Qiagen). cDNA synthesis reaction product
as  then combined with RT2 SYBR Green Mastermix con-
aining  HotStart DNA Taq Polymerase. Reaction mixture
as  then distributed into custom 96-well PCR arrays
http://www.sabiosciences.com/PCRArrayPlate.php).
CR cycling was performed on Applied Biosystems
tepOnePlusTM Real-Time PCR System with cycling
onditions recommended for RT2 SYBR Green PCR quan-
iﬁcation. Post-run threshold cycle (CT) values were
alculated using dedicated ABI software, normalized
o GAPDH and RPLP0, and then transferred to SABio-
ciences PCR Array Data Analysis Template in Excel.
hese ﬁles were then uploaded to the SABioscience web-
ite  (http://sabiosciences.com/pcr/arrayanalysis.php) for
eb-based data analysis and generated plots..6. Selection of genes
Selection  for the majority of the genes evaluated
n this study was based on established changes fromports 1 (2014) 421–434 423
previous arsenic in vitro studies, changes observed in the
gene  array study [26], and some PCR conﬁrmations. JUN
and  FOS have been shown to respond to arsenic challenge
and oxidative stress [34]. The over-expression of JUN has
been  implicated in anchorage-independent growth [35].
Escudero-Lourdes et al. [19,36] also demonstrated pertur-
bations in the expression of a number of pro-inﬂammatory
cytokines. Those included in the study were IL6 and IL8.
In  addition, other inﬂammatory/immune mediators such
as  CXCL10/11, CCRL1, S100A8, IFIT2, and TRIM21 were
also  included. Acute exposure to 50 nM MMA(III) was
found to induce PTGS2 (COX2) expression [18]. Similar
responses have been observed with endothelial cells and
keratinocytes challenged with As(III) [37,38]. Both PTGS1
and  PTGS2 were selected. The previous gene array study
demonstrated a consistent down-regulation of STAT1 and
STAT2  at 1, 2, and 3 months of exposure to MMA(III). STATs
respond to cytokines and growth factors and mediate com-
plex  immune responses [57]. Arsenic has been implicated
in  the suppression of the JAK-STAT pathway based on
in  vitro immunotoxicity studies on HepG2 cells exposed
to  arsenic [39], and animal models of the immune system
[40].  As such, these genes were monitored during the expo-
sure  period in this study, in addition to the STAT1-regulated
IRF1, a regulator of interferon activation, apoptosis and
tumor  suppression. Apoptotic-related genes, PDCDLG2,
CFLAR, GPC3, FAS, and XAF1 were also included to gauge
changes in this particular pathway since apoptosis was an
important  gene ontology term to appear in SPIA analysis of
the  gene array study within the ﬁrst 2 months of exposure.
As  oxidative stress has been implicated in the pathogenesis
from arsenic exposure, genes responsive to oxidative stress
were  also included in the study. Wnek et al. [20] previously
reported the production of ROS and DNA damage in UROtsa
chronically exposed to MMA(III), with signiﬁcant changes
occurring at 3 months of exposure. The genes selected
to monitor oxidative stress were SOD1, OXSR1, MT1X,
DUOX2, GPX8, DUSP1, and CRYAB. The pathway catego-
rization of all of these genes, based on Kyoto Encyclopedia
of Genes and Genomes (http://www.genome.jp/kegg/), is
given in Table 1B.
2.7.  Cell growth kinetics
Growth  curves for UROtsa cells chronically exposed
to 50 nM MMA(III) from 4 to 20 weeks were obtained by
MTT/PMS assay [16]. Alterations in mitochondrial activ-
ity  were used as an indicator of cell viability/growth. The
methylthiazoletetrazolium (MTT, 3-(4,5-dimethylthizol-
2-yl)-2,5-diphenyltetrazolium bromide) assay measures
mitochondrial activity [41]. Cells were seeded in six-well
plates at a density of 32,500 cells per well (n = 4). Cells were
removed from six-well plates with trypsin–EDTA (0.25%)
and  counted by the trypan blue exclusion method. Aver-
age  growth curves were generated based on changes in
cell  number after 24, 48, 72, and 96 h for each of the n val-
ues.  Cell doubling times were calculated using the formula
N/N0 = ekt, where N is the cell number at time t, N0 is the
initial cell number (time 0), and k is a constant. The k value
was  calculated for each time point between 24 and 96 h
and  an average value used to calculate the time t when
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Table  1A
Selected genes for custom RT2 ProﬁlerTM quantitative PCR array. Refseq# is the NCBI reference sequence database number
(http://www.ncbi.nlm.nih.gov/refseq/).  GAPDH and RPLP0 are included in this list since they served as control housekeeping genes for PCR raw
data  analysis. HGDC is a proprietary probe included in the custom arrays for assessing genomic DNA contamination. The genes categorized by pathway
are  given at the end of the table.
Gene symbol Refseq#  Ofﬁcial full name
JUN NM 002228 Jun  proto-oncogene
PDGFRA NM 006206 Platelet-derived growth factor receptor, alpha polypeptide
PDCD1LG2 NM 025239 Programmed cell death 1 ligand 2
CFLAR  NM 003879 CASP8 and FADD-like apoptosis regulator
GPC3  NM 004484 Glypican 3
FAS NM 000043 Fas (TNF receptor superfamily, member 6)
XAF1  NM 199139 XIAP associated factor 1
STAT1  NM 007315 Signal transducer and activator of transcription 1, 91 kDa
STAT2  NM 005419 Signal transducer and activator of transcription 2, 113 kDa
IRF1  NM 002198 Interferon regulatory factor 1
CCRL1  NM 016557 Chemokine (C–C motif) receptor-like 1
SOD1  NM 000454 Superoxide dismutase 1, soluble
OXSR1  NM 005109 Oxidative-stress responsive 1
MT1X  NM 005952 Metallothionein 1X
DUOX2 NM 014080 Dual oxidase 2
GPX8 NM 001008397 Glutathione peroxidase 8 (putative)
DUSP1  NM 004417 Dual  speciﬁcity phosphatase 1
CRYAB  NM 001885 Crystallin, alpha B
DCLRE1C NM 022487 DNA cross-link repair 1C
FOS  NM 005252 FBJ murine osteosarcoma viral oncogene homolog
IL6 NM 000600 Interleukin 6 (interferon, beta 2)
IL8  NM 000584 Interleukin 8
PTGS1 NM 000962 Prostaglandin-endoperoxide synthase 1 (or COX1)
PTGS2 NM 000963 Prostaglandin-endoperoxide synthase 2 (or COX2)
S100A8 NM 002964 S100 calcium binding protein A8
CXCL10  NM 001565 Chemokine (C–X–C motif) ligand 10
CXCL11  NM 005409 Chemokine (C–X–C motif) ligand 11
IFIT2  NM 001547 Interferon-induced protein with tetratricopeptide repeats 2
TRIM21 NM 003141 Tripartite motif containing 21
GAPDH  NM 002046 
RPLP0  NM 001002 
HGDC  SA 00105 
N/N0 = 2, similar to methods described by Butterworth
et al. [42].
2.8.  Colony formation in soft agar
UROtsa cells chronically exposed to 50 nM MMA(III)
from 4 to 20 weeks were assessed for anchorage-
independent growth by colony formation in soft agar
similar to the methods described by Bredfeldt et al.
[16]. Cells were removed from culture ﬂask with 1×
trypsin–EDTA (0.25%) and suspended in DMEM containing
5%  (v/v) FBS and 1% antibiotic–antimycotic supplemented
with 0.3% agar. The agar enriched with cells was  overlaid
onto 0.6% agar medium in a 24-well plate with a density
Table 1B
Selected genes listed by pathways. The genes categorized by pathw
(http://www.genome.jp/kegg/) listings.
Oxidative stress genes MAPK signaling Immune s
SOD1 DUSP1 JUN 
OXSR1 JUN STAT1 
MT1X PDGFRA STAT2 
DUOX2 FOS IRF1 
GPX8 CCRL1 
DUSP1 FOS 
CRYAB TRIM21 Glyceraldehyde-3-phosphate dehydrogenase
Ribosomal protein, large, P0
Human genomic DNA contamination
of  1 × 104 cells per well. After 14 days of incubation,
colonies were manually counted using an Olympus CK2
microscope (Olympus America, Inc., Melville, NY). Data
represent colonies counted from 5 ﬁelds chosen at random
within  each well (n = 3) for a total of 15 ﬁelds.
2.9. SCID mouse colony
A  SCID mouse colony was developed at the Univer-
sity of Arizona using original SCID obtained from Taconic
(Germantown, NY). The mice were housed in microisolator
cages (Allentown Caging Equipment Company, Allentown,
NJ)  and maintained under speciﬁc pathogen-free con-
ditions. The mice were fed NIH-31 irradiated pellets
ay are based on Kyoto Encyclopedia of Genes and Genomes
ystem Inﬂammatory response Apoptosis
FOS PDCD1LG2
IL6 CFLAR
IL8 GPC3
PTGS1 FAS
PTGS2 XAF1
S100A8
CXCL11
CXCL11
IFIT2
ology Reports 1 (2014) 421–434 425
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Fig. 1. Total gene expression change of 29 selected genes from PCR
array study in UROtsa exposed chronically to 50 nM MMA(III) from 4 to
20  weeks. Total expression change for given time interval with red indicat-M. Medeiros et al. / Toxic
Tekland Primier, Madison, WI). Sentinel mice were
creened monthly for mycoplasma, mouse hepatitis virus,
inworms, and Sendai virus via ELISA. Male mice 6–8 weeks
f  age were bled (200 l) by retro-orbital puncture in order
o  screen for the presence of mouse immunoglobulin (Ig)
sing  ELISA. Only mice with Ig levels ≤20 g/ml were used
or  the xenografts experiments.
.10.  Tumorigenicity in SCID mouse xenografts
To assess malignant transformation, UROtsa cells chron-
cally  exposed to 50 nM MMA(III) from 4 to 20 weeks were
njected  subcutaneously (1 × 107 cells per condition) into
he  lower right ﬂank of the mouse in a total volume of
00  l of sterile saline using a 27-gauge needle (Becton
ickinson, Franklin Lakes, NJ). Four mice were used per
ondition. At 60 days from the time of injection, tumor
olumes were measured. The tumor volumes (mm3) were
stimated in accordance with the ellipsoid volume formula,
/3  ×  × a2 × b, where a is the length of minor axis and b is
he  length of the major axis [68]. Mice were euthanized by
arbon  dioxide inhalation until listless and without respi-
ation,  followed by cervical dislocation or exsanguination.
umors were harvested from each animal and portions of
he  tumors were placed in 10% neutral buffered forma-
in  for 24 h then transferred to 70% ethanol. The tissues
ere taken to Cellular Imaging Facility Core at the Univer-
ity  Health Sciences Center. To evaluate histology, tumor
amples were parafﬁn-embedded, sectioned, and stained
ith  hematoxylin and eosin (H&E), and analyzed via light
icroscopy by Dr. David G. Besselsen (Veterinary Pathol-
gist,  University Animal Care, University of Arizona). All
rocedures were performed in accordance with approved
rotocols of the University of Arizona Institutional Animal
are  and Use Committee.
.  Results
Gene expression of pathway markers in UROtsa cells
xposed to 50 nM MMA(III) from 4 to 20 months indicate
erturbations in immune, inﬂammatory, MAPK, and apop-
otic  pathways
PCR  assessment of selected genes showed gradual
hanges early in the exposure period with substantial alter-
tions  in the expression of some genes detected between
2  and 16 weeks of exposure to 50 nM MMA(III). Mea-
ured cumulative expression fold change shows a gradual
ncrease in the absolute magnitude of change as time pro-
resses  with exposure (Fig. 1). From 15 to 20 weeks of
xposure there is a substantial increase in the cumula-
ive fold change in gene expression. The proportion of
own-regulated genes primarily dominates throughout
he proﬁle. Table A.1 lists the direction and magnitude
hanges of genes for the time points evaluated in this study.
The  most perturbed pathway was the inﬂammatory
esponse (Fig. 2). Gradual changes in the expression of
hese  genes between 4 and 12 weeks of exposure give way
o  erratic changes between 13 and 20 weeks of exposure.
enes, such CXCL10 and CXCL11, involved in chemotac-
ic responses, exhibited abnormal expression later in the
xposure  period. CXCL10 expression declined at 13 weeksing summation of fold changes for genes up-regulated and blue indicating
summation of fold changes for genes down-regulated.
of exposure and then peaked at 15 weeks, while CXCL11
expression peaked at 15 weeks of exposure. Arsenic has
been  shown to alter the expression of pro-inﬂammatory
genes PTGS1 and PTGS2 [18,58], however, the expression
changes in PTSG1 and PTGS2 exhibited in this study were
distinctly different in that there was a down-regulation
in PTGS1 expression at around 16 weeks. Both FOS and
PTGS2  expression were down-regulated at 9 and 10 weeks
of  exposure, with FOS expression continuing in this down-
regulated state at 11 and 12 weeks of exposure. Although
not  discernable in Fig. 2, the earliest changes detected were
the  up-regulation of PTGS2 and FOS with at least two-fold
change in expression (Table A.1).
Genes associated with the immune system pathway
exhibited no major changes until between 14 and 20 weeks
of  exposure (Fig. 3). Arsenic is known to impair immune
function, and such changes were characterized in the previ-
ous  gene array study [26]. Although direct effects of arsenic
exposure on STAT2 have not been well established, STAT2
expression within this study peaked at 15 weeks of expo-
sure,  and then declined at 16 weeks. A similar pattern of
change  was  observed for JUN expression. CCRL1, a gene
that  encodes for C–C type chemokine receptors, has been
reported to be involved in cancer invasion and metastasis,
and may  serve as a prognostic marker of cancer progression
[67]. CCRL1 expression was elevated later in the exposure
period, reaching a peak at 20 weeks.
With the exception of a sustained down-regulation of
FOS  from 9 to 12 weeks of exposure, the expression of genes
associated with the MAPK pathway was  not characterized
by major changes until later in the exposure period (Fig. 4).
Gradual  increase in the expression of PDGFRA, a potent
mitogen, with a peak at 15 weeks of exposure was par-
alleled by a gradual increase in JUN expression and slight
elevation in DUSP1 expression. Although not discernable in
Fig.  4, the earliest change detected was  the up-regulation
of PDGFRA, with at least two-fold change in expression
(Table A.1).
Subtle changes occurred in the expression of genes
involved the apoptotic pathway (Fig. 5). More intense
changes in the expression of some of these genes occurred
much later in the exposure period. The expression of CFLAR,
426 M. Medeiros et al. / Toxicology Reports 1 (2014) 421–434
Fig. 2. Plot of the chronological expression of genes associated with the inﬂammatory response in UROtsa cells chronically exposed to 50 nM MMA(III). Plot
CL10, Cdepicts  the level of expression of FOS, IL6, IL8, PTGS1, PTGS2, S100A8, CX
to  50 nM MMA(III) from 4 to 20 weeks.
an inhibitor FAS-induced apoptosis, declined at around
16  weeks of exposure. XAF1 is a known mediator and
inhibitor of apoptosis was down-regulated by 20 weeks of
exposure.  GPC3 has been implicated in the liver cancer,
control of growth factors and apoptosis [61]. Previous gene
array  study demonstrated an elevation in the expression
Fig. 3. Plot of the chronological expression of genes associated with the immune
Plot  depicts the level of expression of JUN, STAT1, STAT2, IRF1, CCRL1 FOS, and T
MMA(III)  from 4 to 20 weeks.XCL11, and IFIT2 relative to control for UROtsa cells exposed chronically
of  GPC3 with 12 weeks of chronic MMA(III) exposure [26];
however, within this study, GPC3 expression did not start
to  increase until 16 weeks of exposure.
Surprisingly, genes involved with oxidative stress did
not  exhibit any substantial change throughout the expo-
sure  period (Fig. 6). Genes such as MT1X and SOD1, which
 system pathway in UROtsa cells chronically exposed to 50 nM MMA(III).
RIM21 relative to control for UROtsa cells exposed chronically to 50 nM
M. Medeiros et al. / Toxicology Reports 1 (2014) 421–434 427
Fig. 4. Plot of the chronological expression of genes associated with MAPK signaling pathway in UROtsa cells chronically exposed to 50 nM MMA(III).
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ave previously been observed altered during short-term
xposure to arsenic, were unaltered [69,70].
A little over a half of the genes surveyed within the PCR
rray  study were in agreement with the change and direc-
ion  of expression measured in the gene array study [26].
f  particular interest was the comparative up-regulation
bserved in PDGFRA, S100A8, and SOD1; and suppression
n  STATs, DUOX2, DUSP1, PTGS1, and PTGS2 at 12 weeks of
xposure  to 50 nM MMA(III).
ig. 5. Plot of the chronological expression of genes associated with apoptosis in U
f  expression of PDCD1LG2, CFLAR, GPC3, FAS, and XAF1 relative to control for URontrol for UROtsa cells exposed chronically to 50 nM MMA(III) from 4 to
3.1. MMA(III) induces hyperproliferation in UROtsa cells
To  determine the transition from a normal to a malig-
nant phenotype in UROtsa cells following chronic exposure
to  50 nM MMA(III), cellular growth rates were assessed
in UROtsa cells chronically exposed to 50 nM MMA(III)
from 4 to 20 weeks (Fig. 7). With increasing time of
exposure to MMA(III), cells displayed an increase in prolif-
eration  rate. Statistical signiﬁcance was found at 16 weeks
ROtsa cells chronically exposed to 50 nM MMA(III). Plot depicts the level
Otsa cells exposed chronically to 50 nM MMA(III) from 4 to 20 weeks.
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ative st
P1, andFig. 6. Plot of the chronological expression of genes associated with oxid
the  level of expression of SOD1, OXSR1, MT1X, DUOX2, GPX8, GPX8, DUS
MMA(III)  from 4 to 20 weeks.
and 20 weeks when compared to UROtsa untreated
control.
3.2. MMA(III) induces anchorage-independent growth of
UROtsa
Anchorage-independent growth is a property displayed
by  many tumorigenic cell lines. Measurement of colony
forming potential allows for the assessment of anchorage-
independent growth. To determine if the increases in
cell  proliferation rates were associated with anchorage-
independent growth, UROtsa cells chronically exposed to
50  nM MMA(III) from 4 to 20 weeks were tested for the
ability  to form colonies in soft agar (Fig. 8). Colony forma-
tion  was detected in UROtsa after 4 weeks of exposure to
Fig. 7. Cell population doubling times for UROtsa exposed chronically to 50 nM MM
but  signiﬁcance was  not reached until 16 weeks of exposure when compared to
difference  (p < 0.02) for the treated cells compared to passage-matched untreated 
Error  bars represent the standard error of the mean.ress in UROtsa cells chronically exposed to 50 nM MMA(III). Plot depicts
 CRYAB relative to control for UROtsa cells exposed chronically to 50 nM
50  nM MMA(III). Colony formation continued to increase in
a  time-dependent manner from 8 to 16 weeks but leveled
off  at 20 weeks.
3.3. MMA(III) enhanced tumorigenicity in UROtsa cells
following 4 weeks of exposure
Because signiﬁcant colony formation was  demon-
strated in nearly all conditions compared to untreated
control, tumorigenicity of select conditions was  then
examined. UROtsa cells exposed to 50 nM MMA(III) for
4  weeks, 8 weeks, 16 weeks, and 20 weeks had signiﬁcantly
elevated tumor burdens compared to control at 60 days
from  the time of injection (Fig. 9). The presence of tumors
at  4 and 8 weeks of exposure was a surprising new ﬁnding,
A(III) from 4 to 20 weeks. Declining trend in doubling times was  apparent,
 UROtsa untreated control (UROtsa). (*) Marks a statistically signiﬁcant
UROtsa following ANOVA detected difference and Bonferroni’s correction.
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Fig. 8. Anchorage-independent growth measured for UROtsa exposed chronically to 50 nM MMA(III) from 4 to 20 weeks. Graphs depict colony formation
measured  after 2 weeks following inoculation of cells into soft agar. Within each well 5 ﬁelds were randomly selected and colonies counted in three
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ifference  and Bonferroni’s correction. Error bars represent the standard 
ince a previous study did not show tumors burdens
ntil 12 weeks of exposure [21]. Although our previous
tudy demonstrated signiﬁcant tumor formation following
2  weeks of exposure, in this study the tumor burden
t 12 weeks of exposure was not statistically different
rom the control. The tumor morphology was indicative
f  squamous cell differentiation and neoplasia/dysplasia
Figs. A.1 and A.2).
.  Discussion
It  has been previously shown that chronic exposure of
ROtsa  to a trivalent monomethylated arsenical, MMA(III),eads  to malignant transformation [16,21]. Gene array anal-
sis  at each month of exposure revealed gradual changes
n  the ﬁrst and second months followed by substantial
lterations in the expression of genes at 3 months that
ig. 9. Tumorigenicity measured for UROtsa exposed chronically from 4 to 20 we
or  60 days to assess tumorigenicity. Tumor volumes were measured twice weekl
ean  tumor burden represents the average tumor volume measured in 4 individua
ith  ANOVA followed by Bonferroni’s correction. (*) Marks statistically signiﬁcan
he  standard error of the mean for each condition.in treated cells compared to untreated UROtsa following ANOVA detected
the mean.
corresponded to phenotypic changes in cellular prolifer-
ation and growth [26].
Within  this more detailed time-course study, low-level
MMA(III) was  shown to perturb the expression of a small
group  genes in the ﬁrst 4 weeks, those associated with the
inﬂammatory response, MAPK signaling, and the immune
system. However, the variable direction in the regulation
of  these genes did not clearly establish a stable alter-
ation associated with direct MMA(III) insult. Hence, the
attempt  to resolve the exposure period into weekly inter-
vals  did not yield any additional information in regards
early gene changes leading to malignant transformation,
as the changes were too subtle. However, the substantial
changes with inﬂammatory genes later in the exposure
period would suggest malignant transformation is likely
consequential of and coupled with these changes. The
results herein also suggest that the effects from expo-
sure to low-level MMA(III) are not strongly linked with
eks in SCID mice. Cells were injected into SCID mice and allowed to grow
y, but data represent only measurements made at 60 days post-injection.
l mice per condition. Signiﬁcant changes in tumor volume were identiﬁed
t changes compared to UROtsa untreated (p ≤ 0.005). Error bars indicate
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elevation in ROS, but more likely an outcome due to the
perturbation in cell signaling cascades that occur further
along  in the exposure period. Genes associated with the
immune, inﬂammatory, MAPK signaling, and apoptosis
pathway appear to be more perturbed than genes involved
with  the oxidative stress response. These results provide
some unique insight on arsenic-induced carcinogenesis,
and demonstrate that even low-level arsenic exposure
must be carefully evaluated, since such considerations on
arsenic  dose and risk thresholds for carcinogenesis are still
being  debated [65].
Arsenic  has been shown to induce the expression of a
number of ROS-responsive genes such as SOD-1, heme oxy-
genase  1 (HMOX-1), NADPH oxidoreductase, glutathione,
heat-shock proteins, and multidrug-resistant transporters
[22,43–46]. These observations have been suggested as
one  of the hallmarks underlining arsenic-induced carcino-
genesis [15,63]. In considering the conditions established,
all  these studies have applied concentrations of arseni-
cals  anywhere from 1 to 25 M for periods of a few
hours to a few weeks, and have utilized animal mod-
els  and other in vitro systems. However, the oxidative
stress genes assessed in the present study did not change
appreciably throughout the exposure period for the low-
level,  non-cytotoxic concentration of the arsenical. A
similar  ﬁnding has been reported, where oxidative stress-
responsive genes did not appear to be signiﬁcantly altered
after  12 weeks of low-level exposure with various trivalent
arsenicals in urothelial cells [24]. Such ﬁndings suggested
that  ROS might be playing a more critical role much earlier
in  the exposure period, or since the concentration is so low
that  oxidative stress is not as important as the effects from
chronic  perturbation in cellular signals.
Perturbations in immunological and inﬂammatory
pathways have long been considered a component in the
development of cancer [60,64]. It has been suggested that
immunological impairment in arsenic-exposed popula-
tions  is a possible mechanism allowing transformed cells
to  survive [59]. Likewise, transformed cells with perturbed
immunological gene expression likely hinder the appro-
priate  response from the immune system. Within this
study, marked perturbations of immunological genes from
MMA(III)  exposure occurred in the latter part of the expo-
sure  period. Additionally, the severe perturbations in the
expression of inﬂammatory genes are reminiscent of the
altered  inﬂammatory responses seen in other studies on
arsenic  exposure ([37,66]; Wu et al., 2008). The inﬂam-
matory cytokine, IL-8, has been reported to increase the
expression of PTGS2 (elevated at 4 weeks of exposure in
this  study) and most likely promotes cell survival and
growth [18,47]. In the weeks that followed, inﬂamma-
tory genes associated with cancer were elevated. At later
time  points (between 12 and 16 weeks of exposure), the
malignant alterations were characterized by the abnor-
mal  expression of STAT1, in addition to FOS, IL-8, and
PTGS2. PTGS2 has been shown to be over-expressed in
aggressive colon cancers [48]. However, arsenic-induced
down-regulation of PTGS2 has only been reported with the
use  of arsenic trioxide in the treatment of acute myeloid
leukemia, HL-60, through the inhibition of NF-kB activity
[49].ports 1 (2014) 421–434
The  effects of arsenic exposure on the MAPK signaling
system have been well documented. Increased cellular pro-
liferation  has been observed with chronic arsenic exposure
[16,50–52]. In this study, signiﬁcant phenotypic changes
were not observed until 16 weeks of exposure. However,
it  is clear that a steady increase in the proliferation rate
was  observed and by 3 months of exposure a 20% change
was  evident when compared to untreated control. Wnek
et  al. [21] ﬁrst reported a signiﬁcant and irreversible change
in  the proliferation rate of UROtsa cells at 3 months of
exposure to MMA(III). In the previous gene array study
perturbations were identiﬁed in the MAPK signaling path-
way  contributing to enhanced proliferation [26]. In the
present study, the proliferation rate assay did not show
a  signiﬁcant change in the doubling time at 4 or 8 weeks
of  exposure. Consequently, DUSP1, a negative regulator of
the  MAPK pathway, was  up-regulated early in the expo-
sure  period, likely attributing to FOS, JUN, and PDGFRA
down-regulation between 8 and 12 weeks of exposure.
Since PDGFRs are distinct mitogens that activate down-
stream effectors such as PI3K, Erk, JNK, and STAT [62],
any  uncontrolled expression of PDGFRs would promote
cell  migration, proliferation, and survival. Up-regulation of
PDGFRA  beginning in latter part of the exposure period
reﬂects one element of enhanced proliferation due to
arsenic-induced carcinogenesis. Coupled to this was the
perturbation in the expression of apoptotic genes. Although
the  expression ﬂuctuates throughout, near the end of the
exposure period there were major changes in the expres-
sion  of XAF1, PDCD1L2, and CFLAR, which could potentially
be  modifying the survival aspects of the cells.
The growth of colonies in soft agar is a commonly
used method to characterize malignant transformation
[16,52,53]. UROtsa cells exposed for 4 weeks to MMA(III)
resulted in the development of colonies in soft agar.
According to a previous study, this period of exposure
was  not sufﬁcient to induce colony formation [21]. As
anchorage-dependent growth is a tightly regulated system
where  cell growth is coupled to signals from growth factor
receptors and integrin [54], it is not clear from the present
study what patterns of gene changes are contributing to the
acquisition  of this phenotype. However, perturbations in
the  expression of IL6 were observed at several points in the
exposure  period, and IL6 has been implicated in anchorage-
independent growth with colorectal carcinoma cell lines
[55].  Another method for determining malignant trans-
formation is to examine the tumorigenicity of cells when
injected into immuno-compromised mice (SCID) [56]. The
development of tumors at 4 weeks of exposure is a new
ﬁnding, and similar to the study on anchorage-independent
growth, not previously seen with this model. These studies
demonstrate that as early as 4 weeks of exposure to low-
level  physiologically-relevant levels of MMA(III), urothelial
cells  acquire phenotypic changes that are characteristic of
a  malignant transformation.
In  summary, the changes observed in the expression
of speciﬁc genes covering a broad range of biological pro-
cesses  from mitogenesis to apoptosis provide a simpliﬁed
picture of alterations that accompany chronic exposure
of  the bladder urothelium to a trivalent arsenical. The
variability of contributing factors in arsenical-induced
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ransformation of UROtsa attests to the very nature of
rsenic-induced carcinogenesis: the path and progression
oward the development of cancer is diverse and arsenic is
ffecting  multiple pathways.
ig. A.1. H&E stain of control untreated UROtsa cells in SCID mice at
0 days post-injection. Legend: (a) edge/fat tissue; (b) disorganized tran-
itional epithelium; (c) vacuolated stratiﬁed squamous epithelial cells; (d)
eratin;  (e) stratiﬁed squamous cells (atypical urothelial morphology).ports 1 (2014) 421–434 431
Transparency document
The  Transparency document associated with this article
can be found in the online version.Appendix A.
Fig. A.2. H&E stain of malignantly transformed UROtsa cells (positive con-
trol)  in SCID mice at 60 days post-injection. Legend: (a) mitotic cells; (b)
vacuolated cells. Overall morphology is indicative of squamous cell dif-
ferentiation and neoplasia/dysplasia.
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Table A.1
Magnitudes of change in the expression of genes in UROtsa cells from 1 month to 6 months of chronic exposure to 50 nM MMA(III).
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